Compare OEC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | REPL |
|---|---|---|
| Founded | 1862 | 2015 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.0M | 407.1M |
| IPO Year | 2014 | 2018 |
| Metric | OEC | REPL |
|---|---|---|
| Price | $7.15 | $5.51 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $6.56 | $5.67 |
| AVG Volume (30 Days) | 708.2K | ★ 4.0M |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,806,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $1.50 |
| 52 Week High | $11.21 | $12.50 |
| Indicator | OEC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 22.79 |
| Support Level | $6.66 | $4.47 |
| Resistance Level | $7.70 | $10.79 |
| Average True Range (ATR) | 0.40 | 0.86 |
| MACD | 0.09 | -0.69 |
| Stochastic Oscillator | 67.69 | 4.64 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.